Status:

COMPLETED

Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection

Lead Sponsor:

Central Hospital, Nancy, France

Conditions:

COVID 19

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The Nancy Cov-H-AKI: study is a prospective, non-randomized, monocenter study performed in patients hospitalised for either the severe or the critical form of Covid-19. The main objective of the Nanc...

Detailed Description

Secondary objectives Evaluate the association of the concentrations at inclusion AND of the variations (between inclusion and 72H post-inclusion) of blood and urine cardiovascular-renal biomarkers of...

Eligibility Criteria

Inclusion

  • Patients over the age of 18,
  • Admission for less than 3 days in the medical service (or in intensive care) for proven serious form of Covid 19 infection (respiratory rate \>30 / min, or desaturation in air ≤ 93%, or PaO2 / FiO2 ≤ 300mmHg)
  • OR Admission for less than 2 days in intensive care (or resuscitation intensive care) for critical form of Covid 19 (shock or respiratory failure).
  • GFR greater than 30 ml / min / 1.73m2.
  • Troponin \<99th percentile.
  • Patient affiliated to a social security scheme or beneficiary of such a scheme
  • The patient or their representative received complete information on the study and signed and dated the emergency situation informed consent/inclusion form in accordance with article L1122-1-3 of the French Public Health Code (Code de la Santé Publique).

Exclusion

  • Exclusion criterion for patients taking part in clinical research.
  • AKI KDIGO grade 1 on the day of visit 1
  • Pregnant women, parturient, or nursing mothers
  • A person of full age subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Person deprived of their liberty by a judicial or administrative decision,
  • Person undergoing psychiatric treatment under articles L. 3212-1 and L. 3213-1 of the Public Health Code.

Key Trial Info

Start Date :

April 27 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 26 2021

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT04354610

Start Date

April 27 2020

End Date

March 26 2021

Last Update

October 1 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

CHRU de Nancy

Nancy, France, 54000

2

CHRU de Nancy

Vandœuvre-lès-Nancy, France, 54500